Biomedical subjects
P Atanasiu
Publications and source records attributed to P Atanasiu.
[Aspects on the new types of antirabic vaccines].
Explore the source record for details and available documents.
[A new rabies vaccine for human use prepared in primary tissue culture (author's transl)].
Explore the source record for details and available documents.
[Diagnosis of rabies by the immunofluorescence and immuno-peroxidase methods].
Explore the source record for details and available documents.
[The preparation of rabies virus nucleocapsid specific IgG and its purification and conjugation with peroxidase or fluorescein isothiocyanate (author's transl)].
Explore the source record for details and available documents.
[Immuno-precipitation of various antigen fractions of fixed and street rabies virus maintained on young mouse brain].
Explore the source record for details and available documents.
[New data on the prevention against human rabies before and after being exposed. New vaccines].
Explore the source record for details and available documents.
[Titration of rabies antibodies practiced on human sera].
Explore the source record for details and available documents.
[Zonal centrifuge purification of human rabies vaccine obtained on bovine foetal kidney cells (author's transl)].
A human rabies vaccine is prepared on bovine foetal kidney cells in absence of serum. This vaccine is concentrated and purified by zonal centrifugation. An immunogenic vaccine is obtained from the purified viral particles. Preliminary results are reported.
[Interferon and antirabies vaccination].
Explore the source record for details and available documents.
[Vaccinations against rabies in France in 1977. I. Vaccinations against rabies at the Pasteur Institute of Paris].
Explore the source record for details and available documents.
[Comparison of inactivated rabies vaccines obtained from diploid and polyploid heterologous cells (Hak, BHK, and Vero)].
Homologous or heterologous diploid or polyploid cells have been established as good producers of virus. In this study we present three types of experimental inactivated antirabies vaccines obtained under identical conditions from three types of cells. The study concerns the following characteristics of the vaccines: protecting powers, rabies antigens and major polypeptidic components; this study was performed on supernatants of tissue cultures and concentrated and purified vaccines. Moreover, some cellular and serum contaminants as well as minor rabies proteins were analysed in the viral solutions. It, thus, appears that all these types of vaccines have a similar protecting power (Number of 50% protective doses/micrograms viral protein).
[Rapid detection of rabies antibodies by immunoenzymatic assay].
The antigen is a semipurified tissue culture virus, and peroxidase conjugated anti-human immunoglobulines are used. When sera from immunized humans are evaluated by this procedure, the values obtained show a good correlation with seroneutralization titres. The detection of antibodies by this method is earlier than by seroneutralization.
[Immunogenicity and protective activity of glycoprotein extracted from rabies virus: results from comparison of preparations obtained by different methods of purification (author's transl)].
A rabies vaccine was prepared from virus grown on primary cultured bovine foetal kidney cells. After beta-propiolactone inactivation of the virus, the vaccine was partially purified by zinc acetate precipitation, G-75 Sephadex chromatography, and ultracentrifugation prior to a non ionic detergent solubilisation. A glycoprotein fraction with protective capacity was extracted by Triton X100 from the spikes of the inactivated rabies virus. An electrophoretically homogenous glycoprotein was found to have higher values of protective activity compared to the initial tissue culture vaccine. T-e yield from this extraction method was from 10 to 20 per cent, based upon an immunological assay.